Franklin Resources
FATE icon

Franklin Resources’s Fate Therapeutics FATE Stock Holding History

Franklin Resources’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,197
Closed -$11.4K – 3173
2025
Q2 		$11.4K Hold
10,197
– – ﹤0.01% 2984
2025
Q1 		$8.06K Sell
10,197
-155,156
-94% -$190K ﹤0.01% 2937
2024
Q4 		$273K Buy
165,353
+14,532
+10% +$36.6K ﹤0.01% 2544
2024
Q3 		$460K Sell
150,821
-79,042
-34% -$308K ﹤0.01% 2309
2024
Q2 		$754K Sell
229,863
-36,146
-14% -$158K ﹤0.01% 2053
2024
Q1 		$1.95M Buy
266,009
+249,498
+1,511% +$1.54M ﹤0.01% 1731
2023
Q4 		$61.8K Sell
16,511
-35
-0.2% -$83 ﹤0.01% 2512
2023
Q3 		$35.1K Sell
16,546
-10,550
-39% -$35K ﹤0.01% 2558
2023
Q2 		$129K Buy
+27,096
New +$150K ﹤0.01% 2489
2022
Q4 		– Sell
-488,558
Closed -$10.9M – 2349
2022
Q3 		$10.9M Sell
488,558
-174,255
-26% -$5.03M 0.01% 906
2022
Q2 		$16.4M Sell
662,813
-1,186
-0.2% -$32.7K 0.01% 837
2022
Q1 		$25.7M Sell
663,999
-19,373
-3% -$750K 0.01% 787
2021
Q4 		$40M Sell
683,372
-5,432
-0.8% -$308K 0.01% 707
2021
Q3 		$40.8M Sell
688,804
-7,532
-1% -$591K 0.02% 708
2021
Q2 		$60.4M Sell
696,336
-61,196
-8% -$4.93M 0.02% 586
2021
Q1 		$62.5M Buy
757,532
+2,590
+0.3% +$248K 0.03% 550
2020
Q4 		$68.6M Sell
754,942
-362,200
-32% -$22.5M 0.03% 511
2020
Q3 		$44.7M Sell
1,117,142
-32,722
-3% -$1.14M 0.02% 580
2020
Q2 		$38.6M Sell
1,149,864
-375
-0% -$11.2K 0.02% 596
2020
Q1 		$25.5M Sell
1,150,239
-613,582
-35% -$15.5M 0.02% 619
2019
Q4 		$34.5M Sell
1,763,821
-554,900
-24% -$8.81M 0.02% 627
2019
Q3 		$36M Sell
2,318,721
-621,800
-21% -$11.9M 0.02% 605
2019
Q2 		$59.7M Sell
2,940,521
-262,500
-8% -$4.73M 0.03% 507
2019
Q1 		$56.3M Sell
3,203,021
-41,685
-1% -$658K 0.03% 501
2018
Q4 		$41.6M Sell
3,244,706
-2,113,559
-39% -$29.5M 0.03% 521
2018
Q3 		$87.3M Sell
5,358,265
-172,484
-3% -$2.04M 0.04% 400
2018
Q2 		$62.7M Sell
5,530,749
-318,030
-5% -$3.5M 0.03% 475
2018
Q1 		$57.1M Sell
5,848,779
-187,000
-3% -$1.79M 0.03% 492
2017
Q4 		$36.9M Sell
6,035,779
-41,100
-0.7% -$183K 0.02% 614
2017
Q3 		$24.1M Hold
6,076,879
– – 0.01% 746
2017
Q2 		$19.7M Hold
6,076,879
– – 0.01% 791
2017
Q1 		$27.6M Hold
6,076,879
– – 0.01% 705
2016
Q4 		$15.1M Buy
6,076,879
+751,879
+14% +$2.01M 0.01% 863
2016
Q3 		$16.6M Buy
5,325,000
+4,825,000
+965% +$11.7M 0.01% 857
2016
Q2 		$850K Hold
500,000
– – ﹤0.01% 1340
2016
Q1 		$900K Hold
500,000
– – ﹤0.01% 1331
2015
Q4 		$1.69M Hold
500,000
– – ﹤0.01% 1318
2015
Q3 		$2.67M Hold
500,000
– – ﹤0.01% 1246
2015
Q2 		$3.23M Buy
+500,000
New +$2.99M ﹤0.01% 1243

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $9.96M AUM 76.57% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources's FATE Position: Q3 2025 in Review

Franklin Resources sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 10,197 shares — an estimated $11.4K sold.

Franklin Resources first reported a position in FATE in Q2 2015 and held it in 39 quarters. The position peaked at $87.3M in Q3 2018. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • Franklin Resources reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Franklin Resources sold 10,197 Fate Therapeutics shares in Q3 2025, an estimated $11.4K.
  • Franklin Resources first reported a position in Fate Therapeutics in Q2 2015 and held it in 39 quarters.
  • Franklin Resources's Fate Therapeutics position peaked at $87.3M in Q3 2018.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on Franklin Resources's 13F filing for Q3 2025, filed 13 Nov 2025.